{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:52:43Z","timestamp":1791103963390,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Swedish Research Council Medicine (VR)"},{"DOI":"10.13039\/501100001728","name":"Swedish Foundation for International Cooperation in Research and Higher Education (STINT)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001728","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.vaccine.2012.02.019","type":"journal-article","created":{"date-parts":[[2012,6,7]],"date-time":"2012-06-07T09:22:14Z","timestamp":1339060934000},"page":"4361-4368","source":"Crossref","is-referenced-by-count":17,"title":["Nasal and skin delivery of IC31\u00ae-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes"],"prefix":"10.1016","volume":"30","author":[{"given":"Benjamin","family":"Wizel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Th\u00f6rn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Harandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.02.019_bib0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.med.59.061606.095540","article-title":"Herpes simplex: insights on pathogenesis and possible vaccines","volume":"59","author":"Koelle","year":"2008","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/eri.09.34","article-title":"Novel approaches in fighting herpes simplex virus infections","volume":"7","author":"Wilson","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group","volume":"282","author":"Corey","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0020","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0025","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1586\/14760584.6.5.741","article-title":"IC31\u00ae and IC30, novel types of vaccine adjuvant based on peptide delivery systems","volume":"6","author":"Lingnau","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"Pt (3)","key":"10.1016\/j.vaccine.2012.02.019_bib0030","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1042\/bj2980623","article-title":"Characterization of the antimicrobial peptide derived from sapecin B, an antibacterial protein of Sarcophaga peregrina (flesh fly)","volume":"298","author":"Yamada","year":"1994","journal-title":"Biochem J"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0035","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1016\/j.vaccine.2006.03.071","article-title":"IC31\u00ae, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses","volume":"24","author":"Schellack","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0040","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1016\/j.vaccine.2008.04.029","article-title":"The novel adjuvant IC31\u00ae strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice","volume":"26","author":"Riedl","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0045","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1016\/j.vaccine.2006.03.072","article-title":"Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31\u00ae","volume":"24","author":"Agger","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0050","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.vaccine.2010.11.003","article-title":"Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells","volume":"29","author":"Aichinger","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0055","doi-asserted-by":"crossref","first-page":"e5930","DOI":"10.1371\/journal.pone.0005930","article-title":"Protection and polyfunctional T cells induced by Ag85B-TB10.4\/IC31\u00ae against Mycobacterium tuberculosis is highly dependent on the antigen dose","volume":"4","author":"Aagaard","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0060","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B-ESAT-6 adjuvanted with IC31\u00ae promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers","volume":"28","author":"van Dissel","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0065","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.4049\/jimmunol.166.5.3451","article-title":"Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract","volume":"166","author":"Gallichan","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0070","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1128\/JVI.02013-05","article-title":"Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes","volume":"80","author":"Tengvall","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0075","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.vaccine.2009.11.035","article-title":"Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice","volume":"28","author":"Del Campo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0080","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.4049\/jimmunol.0900136","article-title":"The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection","volume":"182","author":"Lindqvist","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-1759(98)00015-5","article-title":"The need for IgG2c specific antiserum when isotyping antibodies from C57BL\/6 and NOD mice","volume":"212","author":"Martin","year":"1998","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/viro.1997.8441","article-title":"Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract","volume":"229","author":"Milligan","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0095","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.4049\/jimmunol.160.12.6093","article-title":"T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2","volume":"160","author":"Milligan","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0100","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1099\/0022-1317-82-4-845","article-title":"Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice","volume":"82","author":"Harandi","year":"2001","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0105","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1128\/JVI.72.4.2677-2685.1998","article-title":"Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes","volume":"72","author":"Parr","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0110","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1128\/JVI.75.14.6705-6709.2001","article-title":"Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity","volume":"75","author":"Harandi","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0115","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1006\/viro.1999.9739","article-title":"The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice","volume":"258","author":"Parr","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0120","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1172\/JCI1758","article-title":"Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes","volume":"101","author":"Koelle","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1172\/JCI115888","article-title":"Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth","volume":"90","author":"Ashley","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jri.2007.08.004","article-title":"Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms","volume":"78","author":"Chu","year":"2008","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0165-0378(97)00055-7","article-title":"Protective immunity against HSV-2 in the mouse vagina","volume":"36","author":"Parr","year":"1997","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0140","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1128\/JVI.65.11.6008-6014.1991","article-title":"Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells","volume":"65","author":"Staats","year":"1991","journal-title":"J Virol"},{"issue":"October (2)","key":"10.1016\/j.vaccine.2012.02.019_bib0145","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1046\/j.1365-2567.1998.00587.x","article-title":"Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice","volume":"95","author":"Parr","year":"1998","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0150","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/JVI.79.1.393-400.2005","article-title":"CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides","volume":"79","author":"Jiang","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0155","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","article-title":"Mucosal vaccines: the promise and the challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0160","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0897.2005.00267.x","article-title":"Immunologic uniqueness of the genital tract: challenge for vaccine development","volume":"53","author":"Mestecky","year":"2005","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0165","doi-asserted-by":"crossref","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","article-title":"Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin","volume":"4","author":"Lewis","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0170","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0175","doi-asserted-by":"crossref","first-page":"e3683","DOI":"10.1371\/journal.pone.0003683","article-title":"Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant","volume":"3","author":"Kamath","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0180","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-3083.2008.02225.x","article-title":"IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice","volume":"69","author":"Olafsdottir","year":"2009","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0185","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2010.12.135","article-title":"Ag85B-ESAT-6 adjuvanted with IC31\u00ae promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection","volume":"29","author":"van Dissel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0168-1656(95)00099-2","article-title":"Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants","volume":"44","author":"Chin","year":"1996","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0195","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/S0264-410X(00)00059-1","article-title":"The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity","volume":"18","author":"Enioutina","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0200","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0923-1811(03)00106-3","article-title":"Skin scratching switches immune responses from Th2 to Th1 type in epicutaneously immunized mice","volume":"32","author":"Matsushima","year":"2003","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0205","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1016\/j.vaccine.2011.04.080","article-title":"Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses","volume":"29","author":"Liard","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0210","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jconrel.2010.08.012","article-title":"Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems","volume":"147","author":"Mohanan","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0215","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/infdis\/jir094","article-title":"Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination","volume":"204","author":"Koutsonanos","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0220","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.4049\/jimmunol.0901466","article-title":"What role does the route of immunization play in the generation of protective immunity against mucosal pathogens","volume":"183","author":"Belyakov","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2012.02.019_bib0225","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1016\/j.vaccine.2010.08.082","article-title":"Rabies vaccines: WHO position paper\u2014recommendations","volume":"28","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12001909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12001909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T05:47:16Z","timestamp":1687499236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12001909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":45,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0264410X12001909"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.02.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}